Clinical Trials
7 trialsNCT01573338 2021-04-08
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Bayer
Phase 1/2 Terminated
NCT02161419 2018-06-25
CONCEPT-SCLC
Bayer
Phase 2 Terminated
NCT01188252 2017-01-09
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Bayer
Phase 1 Completed
NCT02522910 2016-08-10
An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Yonsei University
Phase 1/2 Withdrawn
NCT02390154 2016-07-15
Roniciclib Mass Balance Study
Bayer
Phase 1 Completed
NCT02656849 2016-07-01
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02457351 2016-05-23
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
Bayer
Phase 1 Completed